Last reviewed · How we verify

BIIB122 — Competitive Intelligence Brief

BIIB122 (BIIB122) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LINGO-1 inhibitor monoclonal antibody. Area: Neurology.

phase 3 LINGO-1 inhibitor monoclonal antibody LINGO-1 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BIIB122 (BIIB122) — Biogen. BIIB122 is a monoclonal antibody that targets and inhibits LINGO-1, a protein that suppresses myelin repair and regeneration in the central nervous system.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BIIB122 TARGET BIIB122 Biogen phase 3 LINGO-1 inhibitor monoclonal antibody LINGO-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LINGO-1 inhibitor monoclonal antibody class)

  1. Biogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BIIB122 — Competitive Intelligence Brief. https://druglandscape.com/ci/biib122. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: